PTC Therapeutics (PTCT) said Thursday it has filed a new drug application with the US Food and Drug Administration for vatiquinone to treat children and adults with Friedreich's ataxia, a rare neuromuscular disorder.
The application is supported by data from the placebo-controlled MOVE-FA study and two long-term studies that show a "significant" reduction in disease progression and demonstrate a "safe and well-tolerated" vatiquinone across all age groups, the company said.
Price: 45.60, Change: +0.14, Percent Change: +0.31
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments